- Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Device: NIPPV (PALMtop PTV); Device: Volumetric CO2 (NM3); Device: USCOM
Sponsors: Vanderbilt University; Vanderbilt University
Not yet recruiting - verified April 2012 - Condition: Angiotensin-converting Enzyme (ACE) Inhibitor-associated Angioedema
Interventions: Drug: HOE-140; Other: Placebo
Sponsors: Vanderbilt University; Vanderbilt University; University of California, San Diego; Massachusetts General Hospital; University of California, Los Angeles
Recruiting - verified April 2012 - Condition: Eye Allergies
Interventions: Drug: Olopatadine hydrochloride 0.2%; Drug: Bepotastine besilate ophthalmic solution 1.5%
Sponsors: McCabe Vision Center; McCabe Vision Center
Recruiting - verified October 2011 - Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Placebo
Sponsors: Cephalon; Cephalon
Recruiting - verified April 2012 - Condition: Tumor Lysis Syndrome
Intervention:
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified February 2012 - Condition: Asthma
Interventions: Drug: Levalbuterol; Drug: Levalbuterol UDV TID; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified February 2012 - Condition: Suspected Eosinophilic Esophagitis
Intervention: Procedure: Esophageal dilation
Sponsors: Vanderbilt University; Vanderbilt University; Takeda Global Research & Development Center, Inc.
Recruiting - verified July 2011 - Condition: Atopic Dermatitis
Intervention:
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012
 |
Join Clinical Trials in Tennessee for Allergies |
